Supreme Court Lets Takeda's Actos Patent Stand

Law360, New York (April 4, 2008, 12:00 AM EDT) -- The U.S. Supreme Court has snuffed Alphapharm Pty Ltd.'s hopes of soon launching a generic version of Takeda Pharmaceutical Co.'s blockbuster diabetes drug Actos, refusing last week to review an appeals court decision upholding Takeda's patent infringement claims.

The high court denied certiorari March 31 to Alphapharm's petition, filed by the drugmaker in January after the U.S. Court of Appeals for the Federal Circuit rejected its argument that the patent was invalid for obviousness.

The decision effectively upholds the validity of Takeda’s U.S. Patent Number 4,687,777...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.